Ananda Pharma Gets Green Light for Endo Trial
What happened
UK-based Ananda Pharma has received approval from the MHRA and NHS to begin a Phase 2 clinical trial for its cannabidiol-based medicine, ENDOCAN. The trial will test the drug as a potential treatment for endometriosis, a complex and chronic condition.
Why it matters
Endometriosis affects 1 in 10 women of reproductive age in the UK, totaling around 1.5 million individuals. The condition carries a significant economic weight, costing the UK economy an estimated £8.2 billion annually in treatment, healthcare expenses, and work absenteeism. Diagnosis is notoriously slow, with patients waiting an average of 8 years and 10 months from their first GP visit to receive a formal diagnosis. The ENDOCAN-1 trial will be a randomized controlled trial involving 100 women with endometriosis-associated pelvic pain. Over a 12-week period, participants will receive either Ananda's CBD formulation, known as MRX1, or a placebo to gauge the treatment's effectiveness. The study is designed to see if a larger, nationwide trial would be feasible in the future. This Phase 2 trial is a critical step in the drug development process, designed to evaluate the biological effect of the drug and expand on safety testing in a larger group of patients. If the results from this phase are positive, the next step would typically be a larger and longer Phase 3 trial to confirm its effectiveness and monitor long-term safety before it can be considered for market approval. The trial is being led by prominent researchers from the University of Edinburgh, Dr. Lucy Whitaker, a Senior Clinical Research Fellow, and Professor Andrew Horne, a recognized expert in gynaecology and reproductive sciences. The research has received a £300,000 non-dilutive grant from the Chief Scientist Office in Scotland to help fund the study. Cannabidiol (CBD), the active compound in ENDOCAN, is non-psychoactive and is being investigated for its anti-inflammatory and anti-angiogenic properties, which are relevant to the underlying mechanisms of endometriosis. The endocannabinoid system is considered a prime target for endometriosis treatment, and many patients already use CBD or THC to self-treat symptoms. Ananda Pharma is led by CEO Melissa Sturgess, who co-founded the company after researching medicinal cannabis in Israel. The company's strategy focuses on developing regulatory-approved cannabinoid medicines for complex, chronic inflammatory conditions where there is a high unmet medical need.
Key numbers
- UK-based Ananda Pharma has received approval from the MHRA and NHS to begin a Phase 2 clinical trial for its cannabidiol-based medicine, ENDOCAN.
- Endometriosis affects 1 in 10 women of reproductive age in the UK, totaling around 1.5 million individuals.
- The condition carries a significant economic weight, costing the UK economy an estimated £8.2 billion annually in treatment, healthcare expenses, and work absenteeism.
- Diagnosis is notoriously slow, with patients waiting an average of 8 years and 10 months from their first GP visit to receive a formal diagnosis.
What happens next
- The ENDOCAN-1 trial will be a randomized controlled trial involving 100 women with endometriosis-associated pelvic pain.
- Over a 12-week period, participants will receive either Ananda's CBD formulation, known as MRX1, or a placebo to gauge the treatment's effectiveness.
- This Phase 2 trial is a critical step in the drug development process, designed to evaluate the biological effect of the drug and expand on safety testing in a larger group of patients.
Quick answers
What happened in Ananda Pharma Gets Green Light for Endo Trial?
UK-based Ananda Pharma has received approval from the MHRA and NHS to begin a Phase 2 clinical trial for its cannabidiol-based medicine, ENDOCAN. The trial will test the drug as a potential treatment for endometriosis, a complex and chronic condition.
Why does Ananda Pharma Gets Green Light for Endo Trial matter?
Endometriosis affects 1 in 10 women of reproductive age in the UK, totaling around 1.5 million individuals. The condition carries a significant economic weight, costing the UK economy an estimated £8.2 billion annually in treatment, healthcare expenses, and work absenteeism. Diagnosis is notoriously slow, with patients waiting an average of 8 years and 10 months from their first GP visit to receive a formal diagnosis. The ENDOCAN-1 trial will be a randomized controlled trial involving 100 women with endometriosis-associated pelvic pain. Over a 12-week period, participants will receive either Ananda's CBD formulation, known as MRX1, or a placebo to gauge the treatment's effectiveness. The study is designed to see if a larger, nationwide trial would be feasible in the future. This Phase 2 trial is a critical step in the drug development process, designed to evaluate the biological effect of the drug and expand on safety testing in a larger group of patients. If the results from this phase are positive, the next step would typically be a larger and longer Phase 3 trial to confirm its effectiveness and monitor long-term safety before it can be considered for market approval. The trial is being led by prominent researchers from the University of Edinburgh, Dr. Lucy Whitaker, a Senior Clinical Research Fellow, and Professor Andrew Horne, a recognized expert in gynaecology and reproductive sciences. The research has received a £300,000 non-dilutive grant from the Chief Scientist Office in Scotland to help fund the study. Cannabidiol (CBD), the active compound in ENDOCAN, is non-psychoactive and is being investigated for its anti-inflammatory and anti-angiogenic properties, which are relevant to the underlying mechanisms of endometriosis. The endocannabinoid system is considered a prime target for endometriosis treatment, and many patients already use CBD or THC to self-treat symptoms. Ananda Pharma is led by CEO Melissa Sturgess, who co-founded the company after researching medicinal cannabis in Israel. The company's strategy focuses on developing regulatory-approved cannabinoid medicines for complex, chronic inflammatory conditions where there is a high unmet medical need.
